This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e101. Learning Objective-Upon completion of this activity, successful learners will be able to understand the potential role of bile acids in IBS-diarrhea, even when there is not overt bile acid malabsorption.
B
ile acids (BA) are amphiphatic molecules with hydrophobic and hydrophilic regions. They are secreted by the liver into the small intestine in response to feeding to ensure assimilation of lipids and lipidsoluble vitamins. The liver secretes a primary BA pool (chenodeoxycholic acid [CDCA] and cholic acid [CA] ) that is 95% actively reabsorbed in the terminal ileum, with the rest undergoing deconjugation and dehydroxylation by gut microbiota into secondary BA (lithocholic acid [LCA] and deoxycholic acid [DCA] ) in the colon, where they are either passively absorbed or excreted in the feces. 1 BA act on many types of nuclear and membrane bound receptors. 2 There is a delicate equilibrium between gut microbiota, BA pool size/composition, and the human diet.
Approximately 30% of patients with diarrheapredominant irritable bowel syndrome (IBS-D) have BA malabsorption (BAM). 4 In the remaining IBS-D patients without overt BAM, the role of BAs in the pathophysiology of diarrhea is uncertain. In a previous study, we showed an increased proportion of primary BAs (CDCA and CA) in feces of IBS-D patients compared with healthy control subjects, regardless of their total fecal BA excretion, 5 and this increased proportion of primary BAs in feces in IBS-D has been replicated. 6 The proportion of the secondary BA, DCA (which is also secretory), in feces of IBS-D patients was not significantly different from the proportion in healthy control subjects. 5 The concentrations of BAs in the cecum of healthy subjects are unclear. In an autopsy study conducted within 24 hours of death, Hamilton et al 7 estimated the concentrations of the secretory BAs (DCA and CDCA) were 200 and 60 mmol/L, and LCA and CA were 156 and 36 mmol/L, respectively. However, Hamilton et al 7 acknowledged that postmortem changes or the intake of antibiotics before death may have influenced the estimated cecal BA profile and concentrations.
Older studies, based predominantly on enzymatic assays, had estimated that daily total BA excretion in stool in healthy volunteers and patients with idiopathic diarrhea 8 was similar (mean w0.5 mmol/day or w1000 mmol/48 hours), with a higher proportion of primary BAs in stool in idiopathic diarrhea. In the studies of individual stool samples from 3 patients with ileal resection, 9 the fecal excretion of BAs was expressed per gram of stool, and the calculated concentration of CDCA exceeded 10 mmol/L in individual stools. 9 In recent years, liquid chromatography with mass spectrometry has increased the accuracy of BA measurements in serum or stool. 10, 11 In our prior study, 5 we estimated that the total fecal BA concentration was 3.02 AE 0.45 mmol/L in 28 healthy volunteers and 6.08 AE 0.67 mmol/L in 62 unselected patients with IBS-D. Although the proportion of secretory BAs in stool in both groups was approximately 60%, there were higher concentrations in IBS-D patients.
In the cleansed rabbit colon, 12 there was passive absorption of approximately 75% of perfused CDCA through colonic mucosa. In human colonic perfusion studies, Mekhjian et al 13 showed that CA was minimally absorbed, whereas approximately 33% of DCA and approximately 50% of CDCA were absorbed in the colon. LCA is not absorbed in the human colon, because it is extremely insoluble.
14 These data suggest that the concentrations of BAs entering the colon may be up to 2-fold or 3-fold higher than the concentrations of BAs in stool. However, the higher volume of water in the right colon 15 than in stool and the potential for colonic secretion in response to the secretory BAs may actually reduce the concentrations of the BAs. Although it is very difficult to predict the concentrations of BAs in the proximal colon, it is conceivable that patients with diarrhea without definite BAM or ileal resection may have sufficiently high concentrations to stimulate colonic fluid secretion 16 and induce colonic propulsive motility. 17 Our overall hypothesis is that lower concentrations of fecal BAs in patients without overt BAM may cause diarrhea. This hypothesis is based on several observations: 1.0 and 2.5 mM CDCA induced colonic secretion in rabbit colon, 18 1 mM CDCA induced prolonged propagated contractions in humans, and administration (in a delayed-release capsule) of 500 mg or 1000 mg CDCA accelerated colonic transit in healthy control subjects and patients with irritable bowel syndrome-constipation. 19, 20 Our specific hypothesis is that, in IBS-D patients without overt BAM, there is an association between stool BA profile (total and proportion of primary [CDCA and CA] and secretory BAs [CDCA and DCA]) and colon transit and fecal weight.
The primary aim of this study was to explore associations between total fecal BAs, proportions of primary and secretory BAs, and colonic transit measured at 24 hours and 48 hours in IBS-D patients with normal total fecal BA excretion and normal BA synthesis. A secondary aim was to explore associations of those fecal BA measurements with fecal weight in IBS-D patients without overt BAM.
Methods

Study Design
In this cross-sectional, observational study in patients or healthy volunteers participating in research studies in the last 8 years, 5, 10, 21 we appraised bowel functions, total fecal BAs, percentages of fecal BA species, fecal fat, and colonic transit in a convenience sample of 116 patients with IBS-D (by Rome III criteria). Patients for this study were recruited from local communities in southeastern Minnesota to avoid tertiary referral bias. Eligibility criteria, methods of selection, periods of recruitment, and data collection were included in prior publications. 5, 10, 21 We identified patients with IBS-D without evidence of BAM, based on normal fecal total BA excretion or normal synthesis. The data of some of these patients have been published previously 5, 10, 21 ; stool frequency and stool consistency data had been collected during a 2-week period that overlapped with the fecal collections and transit measurements. We used a standard validated bowel pattern daily diary including the Bristol stool form scale, which has been published previously. 22 However, the current study focuses on an analysis of the relationship between BA species and colonic transit, and focuses on IBS-D without overt BAM.
Measurement of Quantitative Traits
Quantitative traits were measured by methods that have been used extensively and validated in our laboratory: fasting serum C4, total and main fecal BA excretion, fecal fat excretion, fecal weight, and scintigraphic colonic transit. [23] [24] [25] [26] [27] [28] These are described briefly in the Supplementary Material.
Statistical Analysis
Bowel function, total and individual fecal BAs, fecal fat, and colonic transit were compared in IBS-D subgroups without overt BAM, identified by fecal BA excretion <2337 mmol/48 hours or by serum C4 <47.1 ng/mL, the upper limit of normal range in our laboratory. 21, 23, 29 Data from 30 healthy volunteers, who were previously recruited by advertisement at Mayo Clinic and screened for bowel symptoms by using a brief questionnaire, 5 were used to compare fecal BA measurements in IBS-D and healthy control subjects. Patients with missing data were excluded from analysis.
We used Spearman correlation coefficients (Rs) to assess associations (based on ranks) between fecal BA measurements and colonic transit, and fecal weight. The a significance level for associations of BA measurements and colonic transit, and fecal weight was adjusted to 0.0036 (for 14 correlations tested). As a form of sensitivity analysis, we also appraised correlations based on fecal BA excretion using the 95th percentile from a healthy volunteer study, which was 2619 mmol/48 hours, to ascertain whether the correlations detected was confirmed.
In addition, we constructed a curve for total fecal BAs and colonic transit by fitting simple models to localized subsets of data to describe the variation in data point by point, using SAS ODS graphics (https://support.sas.com/ rnd/app/ODSGraphics/TipSheet_ODSGraphics.pdf). This is termed LOESS (locally weighted scatterplot smoothing), a statistical method developed by Cleveland and Devlin. 30 The smoothing value was selected automatically by the program, that is, 2/number of observations. The LOESS option in SGPLOT from SAS does not create a residual plot. All analyses were performed using SAS version 9.3 (Cary, NC). Tables 1 and 2 summarize demographics, fasting serum C4, total fecal BAs, proportions of primary (CDCA and CA) and secretory (CDCA and DCA) BAs out of total fecal BAs, fecal fat, and colonic transit (GC24, GC48) of the group of 116 IBS-D patients. Complete data were available in 110 patients and were tabulated for those with either 1 or both tests being normal or abnormal. Reasons for lack of availability were technical problems with assay or patient choice. Subgroups were based on fecal BA excretion and BA synthesis (fasting serum C4). The patients ( Table 2 ) with higher fecal BA excretion and fasting serum C4 (n ¼ 36) compared with those with normal values (n ¼ 74) had significantly higher body mass index (32.0 AE 1.5 compared with 25.6 þ 0.5 kg/m 2 , respectively; P < .001). Table 3 shows concentrations of total and main fecal BAs in the 91 IBS-D patients with normal serum C4 (<47.1 ng/mL), in the 86 patients with total fecal BAs (<2337 mmol/48 hours), and data from 30 healthy control subjects studied in our laboratory and previously published in the literature. 5 There were (as expected, given the selection of patients for this analysis) no differences in total fecal BAs or percent of individual BAs between the 86 patients with total fecal BAs (<2337 mmol/48 hours) and the 91 patients with serum C4 (<47.1 ng/mL). Seventy-four patients had both total fecal BA excretion <2337 mmol/48 hours and serum C4 <47.1 ng/mL (Table 2) . Although the total fecal BA in the 30 healthy control subjects was not significantly different compared with the 2 IBS-D groups, there was 4.6-fold or 8-fold higher estimated CDCA concentration and 3.9-fold or 8.3-fold higher CA concentration in the 2 IBS-D groups compared with healthy control subjects. In contrast, the fold differences for estimated DCA and LCA concentrations were all <1.5-fold relative to healthy control subjects.
Results
Demographics and Phenotype
Concentrations of Total and Main Fecal Bile Acids
Correlations of Fecal Bile Acids and Fecal Weight in Irritable Bowel Syndrome-Diarrhea Subgroup Without Bile Acid Malabsorption
A significant correlation was observed between total fecal BAs and fecal weight (Rs ¼ 0.72; P < .0001) in the group with normal BA synthesis (serum C4 <47.1 ng/mL). Correlations between these quantitative measurements were also present in the group with normal BA excretion (total fecal BAs <2337 mmol/48 hours) with Rs ¼ 0.57 (P < .0001).
Correlations of Fecal
In the subgroup (91 of 116) of IBS-D patients with normal BA synthesis (serum C4 <47.1 ng/mL), several significant associations were present (Table 4) , consistent with moderate-strength correlations. Colonic transit GC24 and GC48 were significantly associated with fecal total BAs and fecal primary BAs (all P < .0036). The correlation between colonic transit GC48 and proportion of secretory BAs (CDCA and DCA) was borderline significant (P ¼ .0062, above the threshold of .0036).
Correlations of Fecal Bile Acids and Colonic Transit in Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption Based on Normal Total Fecal Bile Acid Excretion
In the subgroup (86 of 116) of IBS-D patients with normal BA excretion (total fecal BA <2337 mmol/48 hours), several significant associations were observed (Table 5) . Colonic transit at 48 hours was significantly associated with fecal total BAs, fecal primary Bas, and fecal secretory BAs (all P < .0036). However, no significant associations were present with those fecal BA measurements and colonic transit at 24 hours. When the data were analyzed for the 89 of 116 patients with total fecal BA excretion <2619 mmol/48 hours, all the significant correlations were confirmed.
Characterization of Relationships Between Bile Acid and Colonic Transit Shown by LOESS Analysis
LOESS curves were generated to visualize the associations between total fecal BAs or serum C4 and GC48 in the entire patient cohort (!2237 and <2337 mmol/48 hours, or >47.1 and <47.1 ng/mL), without specifying a regression function. In Figure 1 , the LOESS curves show a steep slope for "normal" values of total fecal BAs or serum C4, but they flatten above the upper limit of normal range (approximately at 2400 mmol/48 hours for total fecal BAs and at approximately 40 ng/mL for serum C4). The curves suggest that, within the normal range of BA excretion, there is an important impact of fecal BA excretion or BA synthesis (for which C4 is a surrogate) on colonic transit GC48.
Discussion
Our study shows that in IBS-D patients without overt BAM, total fecal BAs is significantly correlated with fecal weight. In addition, increased total fecal BAs and proportions of primary and secretory BAs are associated with colonic transit at 24 and 48 hours. Furthermore, as illustrated in Figure 1 , among IBS-D patients without overt BAM, fecal BAs impact colonic transit, as shown in the more vertical part of the LOESS curves in contrast to the more horizontal relationship between fecal total BAs and colonic transit among those with overt BAM. Overall, these results suggest that total fecal BA levels that do not represent overt BAM, and alterations in the fecal BA profile, are associated with colonic transit and increased fecal weight in IBS-D patients. BAs have been ingested for centuries in Oriental civilizations to relieve constipation. [31] [32] [33] Delivery of BAs to the colon (CDCA in an ileocolonic release capsule) accelerated colonic transit in healthy control subjects and patients with irritable bowel syndrome-constipation. 19, 20 Compared with healthy volunteers from our previous study, 5 IBS-D patients without elevated BA excretion or synthesis in the current study had increased total fecal BAs and primary BAs (including elevated CDCA), and increased absolute concentrations of secretory BAs (Table 3) .
BAs may affect either colonic secretion or motility. The infusion of BAs (CDCA and DCA) in the cecum of healthy volunteers inhibited absorption and induced secretion of water and electrolytes (sodium ion and chloride ion), 34 effects associated with di-a hydroxy BA chemistry. [35] [36] [37] In fact, our study shows that the proportions of fecal CDCA and DCA (both di-a hydroxy BA) are significantly associated with increased colonic transit. CDCA has been considered the main secretagogue 9, 38 ; in IBS-D, our previous studies showed that the proportion of DCA in stool was on average 56% (similar to the proportion in healthy control subjects), and the proportion of CDCA was approximately 2%. Nevertheless, the concentration of CDCA in feces of IBS-D patients is higher than in healthy control subjects and may promote secretion. 5 The effects of CDCA and DCA on colonic motility may result from increased phasic pressure activity or from the motor responses secondary to colonic secretion. Goy et al 8 showed that total fecal BA levels in idiopathic diarrhea were similar to those of healthy control subjects, but the patients with diarrhea had increased fecal primary BAs (of which CDCA is secretory and CA is nonsecretory), and there were higher fecal water and (nonsignificantly) higher fecal weight, fecal sodium ion, and potassium. However, the latter changes were not significant because of a type II statistical error, because with the observed variance in fecal weight, approximately 65 patients (rather than the 12 studied) per group would be required for the observed difference in fecal weight to be statistically significant.
The effects of BAs leading to acceleration of colonic transit may also reflect effects on colonic motility. Kirwan et al 39 found correlations between increased fecal primary BAs and colonic motility index in patients with chronic diarrhea. Infusion of CDCA and supraphysiologic concentrations (15 mM) of DCA in the sigmoid of IBS patients 40 stimulated colonic motility. Falconer et al 41 found that 3-30 mM DCA elicited colonic motor activity in the rabbit sigmoid, whereas similar amounts of CA did not. More recently, Bampton and colleagues 17 concluded that rectal infusion of CDCA (w2 mM) is a potent stimulus for propagating pressure waves in the proximal colon in humans.
Molecular mechanisms of BA-induced motility are attributed to the G-protein coupled BA receptor 1 (GPBAR1, also known as TGR5). The membrane-bound receptor, TGR5, 42 also mediates the effects of BAs on glucose homeostasis (via GLP-1 release by intestinal enteroendocrine cells), inflammation, and BA synthesis and excretion. 2 Poole et al 43 demonstrated TGR5 on neurons of the submucosal and myenteric plexus in the murine small bowel and colon, chiefly in nitric oxide synthase-positive inhibitory neurons (>80% TGR5 positive). 43 TGR5 plays a role in the peristaltic reflex evoked by BAs in the colon in a mouse model. 44 BA-induced secretion and colonic motility are not mutually exclusive effects. Thus, increased secretion with greater intraluminal volume can act as a mechanical stimulus of motility. Accelerated transit may lead to greater BA excretion in stool (lack of time to reabsorb BAs by passive, diffusion-related mechanisms) and, possibly, to altered fecal BA profile (lack of time for bacterial dihydroxylation) with higher proportion of primary BAs. Proof of the importance of accelerated transit on BA kinetics is demonstrated by the effects of loperamide in patients with chronic radiation enteritis and chronic diarrhea; loperamide resulted in slowing transit and more BA absorption. 45, 46 
Strengths and Limitations
Our study included a large sample, which made it possible to perform advanced statistical analyses, such as the LOESS method, to support the hypotheses about the biologic effects of relatively smaller perturbations of BA homeostasis than have been observed in overt BAM. The correlations reported are statistically significant, even with correction for multiple correlations, with an alpha level of 0.0036. The in vivo measurements with extensively validated techniques take into account the complex, integrative physiology modulating the effects of BAs.
A limitation of our study is that fecal electrolytes and fecal microbiome were not studied. Therefore, we cannot appraise the potential role of dysbiosis in the altered fecal BA pool composition. A second limitation is that, despite refined and accurate measurement techniques of fecal individual BAs, it is difficult to deduce the precise BA concentrations and composition delivered into the cecum that actually influenced the colonic secretion and motility. 7 
Conclusions
Our study shows that total fecal BAs and the fecal BA profile are significantly associated with fecal weight and colonic transit in IBS-D patients without overt BAM; the data are consistent with moderate-strength correlations. There is a range of BA excretion in patients with IBS-D. Our data suggest a mechanistic role for borderline high BA synthesis or excretion and an altered BA profile in the diarrhea in some patients with IBS, with increased proportions of primary BAs or secretory BAs, particularly the CDCA content of stool. Future studies will test this hypothesis by examining the effects of BA sequestrants, FGF-19 analogues, or FXR agonists in patients with IBS-D without overt BAM. The impact on clinical practice in the near future is that measurement of BA kinetics may identify patients with functional diarrhea in the absence of overt BAM in whom therapy may be directed at restoring normal BA synthesis or excretion.
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